|
|||
|
Assessment of Anticholinergic Use After Fading of BTX-A Effects in Refractory Idiopathic Overactive Bladder: A Prospective Blinded Randomized Trial
M.A. Elbaset, Diaa-Eldin Taha, Ahmed S. El-Hefnawy, Mohamad H. Zahran, A.A Shokeir
Int Neurourol J. 2019;23(3):240-248. Published online 2019 Sep 30
DOI: https://doi.org/10.5213/inj.1938098.049 |
|||
|
Citations to this article as recorded by  Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults
Akvile Stoniute, Priya Madhuvrata, Madeleine Still, Evelyn Barron-Millar, Ghulam Nabi, Muhammad Imran Omar
Cochrane Database of Systematic Reviews.2023;[Epub] CrossRef Long-term botulinum therapy for overactive bladder: myths and reality
Igor V. Kuzmin, Margarita N. Slesarevskaya, Refat E. Amdiy, Tatiana V. Ulitko, Salman Kh. Al-Shukri
Urology reports (St. - Petersburg).2022; 12(1): 71. CrossRef Treatment outcomes of overactive bladder with combined therapies of botulinum toxin injections and oral agents
Abbigail Woll, Autumn Edenfield, Mallory Locke, Steven Swift
International Urogynecology Journal.2021; 32(10): 2803. CrossRef Catheter-Related Bladder Discomfort: How Can We Manage It?
Eun Bi Jang, Seong Hwi Hong, Kyu Shik Kim, Sung Yul Park, Yong Tae Kim, Young Eun Yoon, Hong Sang Moon
International Neurourology Journal.2020; 24(4): 324. CrossRef
|
